Bayer CEO advocates for 'speedboat' agility in large firms
What happened
Bayer CEO Bill Anderson is implementing a "speedboat" approach to increase agility at the 100,000-employee company. In a recent discussion, he outlined a focus on flattening hierarchy, empowering teams, and increasing the velocity of decision-making to turn around the legacy organization.
Why it matters
- This strategic shift, internally named "Dynamic Shared Ownership," aims to dismantle traditional hierarchies and empower self-managed teams. The goal is for 95% of decisions to be made by the people closest to the work, with innovation cycles shortening to 90 days. - Bill Anderson, who became CEO in June 2023, has a background in chemical engineering and previously served as CEO of Roche Pharmaceuticals and Genentech. His experience includes leading a major transformation program at Roche that resulted in significant revenue growth. - The restructuring is not just about speed but also a response to significant financial pressures, including the ongoing litigation Bayer inherited with its $63 billion acquisition of Monsanto in 2018. The company has already paid over $10 billion to settle claims that the Roundup herbicide causes cancer. - As part of the overhaul, Bayer has reduced its workforce by approximately 12,000 positions, with about half of those being management roles. This flattening of the organization is a core component of the "Dynamic Shared Ownership" model. - The "speedboat" analogy is part of a broader trend in large enterprises toward organizational agility, with frameworks like the Scaled Agile Framework (SAFe) and models like Scrum@Scale aiming to improve responsiveness and decision-making speed. - Early results from the new model have shown promise, with one consumer health team in Southeast Asia shortening internal processes by 60% and moving product launch dates forward by five to nine months. In the U.S. Pharmaceuticals division, 68 customer-focused "squads" have replaced four larger franchises. - Investor confidence has seen a notable recovery, with Bayer's stock price rebounding from lows in early 2025 to the mid-€40s by early 2026, driven by restructuring efforts and positive clinical trial news. However, analysts note that ongoing litigation and balance sheet risks remain key concerns. - The company is also pursuing a legal and legislative strategy to manage the Roundup litigation, including an appeal to the U.S. Supreme Court and lobbying for state-level legislation that would preempt failure-to-warn claims.
Key numbers
- Bayer CEO Bill Anderson is implementing a "speedboat" approach to increase agility at the 100,000-employee company.
- The goal is for 95% of decisions to be made by the people closest to the work, with innovation cycles shortening to 90 days.
- Bill Anderson, who became CEO in June 2023, has a background in chemical engineering and previously served as CEO of Roche Pharmaceuticals and Genentech.
- The restructuring is not just about speed but also a response to significant financial pressures, including the ongoing litigation Bayer inherited with its $63 billion acquisition of Monsanto in 2018.
What happens next
- This strategic shift, internally named "Dynamic Shared Ownership," aims to dismantle traditional hierarchies and empower self-managed teams.
- Early results from the new model have shown promise, with one consumer health team in Southeast Asia shortening internal processes by 60% and moving product launch dates forward by five to nine months.
Quick answers
What happened in Bayer CEO advocates for 'speedboat' agility in large firms?
Bayer CEO Bill Anderson is implementing a "speedboat" approach to increase agility at the 100,000-employee company. In a recent discussion, he outlined a focus on flattening hierarchy, empowering teams, and increasing the velocity of decision-making to turn around the legacy organization.
Why does Bayer CEO advocates for 'speedboat' agility in large firms matter?
This strategic shift, internally named "Dynamic Shared Ownership," aims to dismantle traditional hierarchies and empower self-managed teams. The goal is for 95% of decisions to be made by the people closest to the work, with innovation cycles shortening to 90 days. Bill Anderson, who became CEO in June 2023, has a background in chemical engineering and previously served as CEO of Roche Pharmaceuticals and Genentech. His experience includes leading a major transformation program at Roche that resulted in significant revenue growth. The restructuring is not just about speed but also a response to significant financial pressures, including the ongoing litigation Bayer inherited with its $63 billion acquisition of Monsanto in 2018. The company has already paid over $10 billion to settle claims that the Roundup herbicide causes cancer. As part of the overhaul, Bayer has reduced its workforce by approximately 12,000 positions, with about half of those being management roles. This flattening of the organization is a core component of the "Dynamic Shared Ownership" model. The "speedboat" analogy is part of a broader trend in large enterprises toward organizational agility, with frameworks like the Scaled Agile Framework (SAFe) and models like Scrum@Scale aiming to improve responsiveness and decision-making speed. Early results from the new model have shown promise, with one consumer health team in Southeast Asia shortening internal processes by 60% and moving product launch dates forward by five to nine months. In the U.S. Pharmaceuticals division, 68 customer-focused "squads" have replaced four larger franchises. Investor confidence has seen a notable recovery, with Bayer's stock price rebounding from lows in early 2025 to the mid-€40s by early 2026, driven by restructuring efforts and positive clinical trial news. However, analysts note that ongoing litigation and balance sheet risks remain key concerns. The company is also pursuing a legal and legislative strategy to manage the Roundup litigation, including an appeal to the U.S. Supreme Court and lobbying for state-level legislation that would preempt failure-to-warn claims.
